Clinical trials: Facial Neoplasms
Actinic Keratosis
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
- Trial name
- NCT06319794
- Testing
- Bimiralisib
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- TORQUR
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00915551
- Testing
- PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 278 people
- Sponsor
- Peplin
Actinic Keratoses
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.
- Trial name
- NCT00427050
- Testing
- PEP005
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 50 people
- Sponsor
- Peplin
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
Actinic Keratosis
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/…
- Trial name
- NCT01787383
- Testing
- Ingenol mebutate gel 0.05 %, Ingenol mebutate gel 0.015 %
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA
Actinic Keratosis
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups.
- Trial name
- NCT02124239
- Testing
- Ingenol mebutate
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- LEO Pharma
Ptosis, Ptosis, Mild
Performance and Safety Assessment of SPRING THREAD® Elastic Tensor Thread in Patients With Mild to Moderate Facial Ptosis.
The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SPRING THREAD® elastic tensor thread.
- Trial name
- ESTES (NCT05746078)
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- 1st SurgiConcept
Actinic Keratosis
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00916006
- Testing
- PEP005 Gel, Vehicle gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 269 people
- Sponsor
- Peplin
Actinic Keratoses
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.
- Trial name
- NCT00786994
- Testing
- Oleogel-S10 100 mg/g
- Where
- 6 sites in Germany, Greece
- Volunteers
- 165 people
- Sponsor
- Birken AG
Gorlin Syndrome
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
- Trial name
- NCT06050122
- Testing
- Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 113 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris
Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne
This study was conducted to determine the effects and side effects of ProOxy facial spray in the treatment of acne.
- Trial name
- NCT01682200
- Testing
- ProOxy
- Where
- 2 sites in Philippines
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medivet Pty Ltd
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Actinic Keratosis (AK)
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a…
- Trial name
- NCT07729579
- Testing
- Investigational drug, Photodynamic therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Mandible Tumor, Mandibular Injuries
Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction
EpiBone-Craniomaxillofacial (EB-CMF) is an autologous, anatomically shaped bone graft created specifically for the patient's defect, using the patients own adipose-derived mesenchymal stem cells.
- Conditions
- Mandible Tumor, Mandibular Injuries, Mandible; Deformity
- Trial name
- EB-CMF (NCT03678467)
- Testing
- EB-CMF
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Epibone, Inc.
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Facial Angiofibroma, Tuberous Sclerosis
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT03826628
- Testing
- rapamycin
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 107 people
- Sponsor
- Dermatology Specialties Limited Partnership